Ips Heart’s stem cell therapy designated orphan drug for Becker muscular dystrophy
Jan. 14, 2025
Ips Heart Inc. has been awarded orphan drug designation by the FDA for its GIVI-MPC stem cell therapy for Becker muscular dystrophy. GIVI-MPC has the unique ability to create new muscle with full length dystrophin in Becker muscular dystrophy.